| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 6/6 |
Rewards
Risk Analysis
No risks detected for 500672 from our risk checks.
Novartis India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,156.00 |
| 52 Week High | ₹1,224.00 |
| 52 Week Low | ₹599.95 |
| Beta | 0.39 |
| 11 Month Change | 5.08% |
| 3 Month Change | 9.56% |
| 1 Year Change | 56.72% |
| 33 Year Change | 20.50% |
| 5 Year Change | 84.65% |
| Change since IPO | 192.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500672 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.8% | 2.2% | -1.0% |
| 1Y | 56.7% | 46.7% | 43.6% |
Return vs Industry: 500672 exceeded the Indian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: 500672 exceeded the Indian Market which returned 43.6% over the past year.
Price Volatility
| 500672 volatility | |
|---|---|
| 500672 Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 500672 has not had significant price volatility in the past 3 months.
Volatility Over Time: 500672's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 62 | Vas Narasimhan | www.novartis.in |
Novartis India Limited operates as a healthcare company in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neurosciences products under the Tegrital and Exelon brands.
Novartis India Limited Fundamentals Summary
| 500672 fundamental statistics | |
|---|---|
| Market cap | ₹28.54b |
| Earnings (TTM) | ₹851.90m |
| Revenue (TTM) | ₹3.35b |
33.5x
P/E Ratio8.5x
P/S RatioIs 500672 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500672 income statement (TTM) | |
|---|---|
| Revenue | ₹3.35b |
| Cost of Revenue | ₹2.00b |
| Gross Profit | ₹1.35b |
| Other Expenses | ₹499.10m |
| Earnings | ₹851.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 29, 2024
| Earnings per share (EPS) | 34.50 |
| Gross Margin | 40.32% |
| Net Profit Margin | 25.42% |
| Debt/Equity Ratio | 0.003% |
How did 500672 perform over the long term?
See historical performance and comparison